Innoviva Files 13D/A for Armata Pharmaceuticals

TL;DR

Innoviva updated its Armata stake filing on 3/4/24. Watch for ownership changes.

AI Summary

Innoviva, Inc. has amended its Schedule 13D filing regarding Armata Pharmaceuticals, Inc. on March 4, 2024. The filing indicates a change in the beneficial ownership of Armata Pharmaceuticals, Inc. by Innoviva, Inc. and its subsidiary, Innoviva Strategic Opportunities LLC. Specific details on the percentage of ownership or the exact number of shares are not provided in this excerpt.

Why It Matters

This filing signals a potential shift in control or significant stakeholding in Armata Pharmaceuticals by Innoviva, which could impact the company's strategic direction and stock performance.

Risk Assessment

Risk Level: medium — Changes in beneficial ownership filings can indicate strategic moves by major shareholders, potentially leading to volatility.

Key Players & Entities

• Innoviva, Inc. (company) — Filing entity
• Armata Pharmaceuticals, Inc. (company) — Subject company
• Innoviva Strategic Opportunities LLC (company) — Subsidiary of Innoviva, Inc.

FAQ

Key Financial Figures

• $0.01 — , INC. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securitie
• $35,000,000 — h the Issuer borrowed from Innoviva Sub $35,000,000 on terms and conditions similar to thos

Filing Documents

• ef20023182_sc13da.htm (SC 13D/A) — 82KB
• 0001140361-24-011136.txt ( ) — 84KB

in Schedule 13D is hereby supplemented as follows

Item 4 in Schedule 13D is hereby supplemented as follows: On March 4, 2024, the Issuer entered into, as borrower, a credit and security agreement (the "March 2024 Credit Agreement") with Innoviva Sub, pursuant to which the Issuer borrowed from Innoviva Sub $35,000,000 on terms and conditions similar to those set forth in the secured credit and security agreement between the parties dated as of July 10, 2023 (the "July 2023 Credit Agreement"). On the date of this Amendment No. 10, the Reporting Persons collectively own 25,076,769 shares of Common Stock of the Issuer, warrants to acquire an additional 19,364,647 shares of Common Stock of the Issuer, and the right to acquire an additional 19,736,843 shares of Common Stock of the Issuer upon conversion of the convertible loan (excluding any accrued interest). Item 5. Interest in Securities of the Issuer

in Schedule 13D is hereby supplemented as follows

Item 5 in Schedule 13D is hereby supplemented as follows: As of the date of this filing of Amendment No. 10, the Reporting Persons collectively may be deemed to have beneficial ownership of 64,178,259 shares of Common Stock, representing approximately 85.3% of the outstanding shares of Common Stock of the Issuer as of the date of this Amendment No. 10 to Schedule 13D, based on 36,146,574 shares of Common Stock outstanding as of November 10, 2023, as set forth on the Issuer's Quarterly Report on Form 10-Q, plus 19,736,843 shares of Common Stock issuable upon the conversion of a certain convertible loan held by the Reporting Persons (excluding any accrued interest) and shares of Common Stock issuable upon exercise of the warrants to purchase Common Stock beneficially owned by the Reporting Persons. Except as set forth in this Schedule 13D (as amended), the Reporting Persons did not acquire or sell any shares of Common Stock or other securities of the Issuer during the last 60 days. Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer

in Schedule 13D is hereby supplemented as follows

Item 6 in Schedule 13D is hereby supplemented as follows: On March 4, 2024, the Issuer and Innoviva Sub entered into the March 2024 Credit Agreement pursuant to which the Issuer borrowed from Innoviva Sub $35,000,000 on terms and conditions similar to those set forth in the July 2023 Credit Agreement. In connection with the parties' entry into the March 2024 Credit Agreement, the Issuer and Innoviva Sub and the other parties thereto (as applicable) entered into amendments to (i) the secured convertible credit and security agreement, dated January 10, 2023, by and among the Issuer, Innoviva Sub and the other parties thereto (as amended, the "Convertible Credit Agreement" and such amendment, the "Second Amendment to Convertible Credit Agreement") and (ii) the July 2023 Credit Agreement (such amendment, the "First Amendment to July 2023 Credit Agreement" and together with the Second Amendment to Convertible Credit Agreement, the "Amendments") which Amendments conform certain terms relating to permitted indebtedness and permitted liens both to match the corresponding terms in the March 2024 Credit Agreement and to permit the same. The March 2024 Credit Agreement is not convertible into securities of the Issuer or into any other securities. The March 2024 Credit Agreement is further described in the Issuer's Form 8-K filed with the SEC on March 4, 2024. The foregoing descriptions of the terms of the March 2024 Credit Agreement, of the First Amendment to July 2023 Credit Agreement and of the Second Amendment to Convertible Credit Agreement do not purport to be complete and are qualified in their entirety by the full texts of such agreements, copies of which are filed as Exhibits 10.1, 10.2 and 10.3, respectively, to the Form 8-K of the Issuer filed with the SEC on March 4, 2024. 4 SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: March 4, 20

View Full Filing

View this SC 13D/A filing on SEC EDGAR